


carbonyl olefination at the α -carbon atom of a preformed 4-substituted bithiazole.

In this paper we provide a full account on our endeavour directed towards the synthesis of cystothiazoles. Two pathways have been explored which differ in the order of events and which are depicted for cystothiazole **E** as possible target in Scheme 1. Both routes rely on the readily available 2'-isopropyl-4-bromo-2,4'-bithiazole (**4**). Its synthesis has been



Scheme 1. Retrosynthetic strategy for the preparation of cystothiazole **E** (**1e**) from precursors **2**–**5**.

optimized^[7] and it is available from 2,4-dibromothiazole in 70% overall yield. Crucial to the success of all pathways is the cross-coupling at the 4-position of this substrate. The reactivity at this position is low and careful experimentation was necessary to find suitable conditions which allowed for a C–C-

bond formation. In route I which has already been published in preliminary form^[6] we followed a convergent approach and tried to establish bond *b* as late as possible in the synthesis. As it turned out, the aldol reaction of the *N*-propionyl oxazolidinone **2** and aldehyde **3** proceeded readily (bond *c*) but it was not sensible from a practical point of view to establish bond *d* prior to the cross-coupling (see below). Route II has been developed more recently which aimed at a bond construction in the order *a-b-c-d*. Although more linear than route I it was appealing to us because it allowed for a formal access to other cystothiazoles such as cystothiazoles **A** (**1a**) and **C** (**1c**). Stannane **5**^[8] proved to be the key building block in this strategy.

Results and Discussion

Attempted cross-coupling reactions with substrate **4:** Previous work in our group had revealed that a Pd-catalyzed cross-coupling with a 2-arylsubstituted 4-bromothiazole is not easy to achieve.^[9, 10] Suzuki reactions with arylboronic acids, however, have been shown to work quite well.^[11] In addition, there was literature precedence for successful Stille and Sonogashira cross-coupling reactions^[12] conducted with 4-bromothiazoles^[13, 14] and with the activated 4,4'-dibromo-2,2'-bithiazole.^[15] Stannylations at 4-bromothiazoles with hexamethylditin had also been reported.^[16] We were most intrigued by the fact that Heck reactions had been carried out with 4-bromothiazole although the reported yields were low (5–19%).^[14a] In fact, a Heck reaction would have allowed for a connection between a complete aldol fragment and bithiazole **4**. Preliminary experiments were conducted with alkenes **6**, **7**, and **8** (Figure 2) but there was no indication for a successful coupling to bithiazole **4**. Conditions [Pd(OAc)₂, P(*o*-Tol)₃, K₂CO₃ in *N,N*-dimethylacetamide (DMA)], which in our hands facilitated a rapid and smooth Heck reaction of acrylate **8** with bromobenzene, failed completely for the 4-bromobithiazole **4**.





Figure 2. Potential reaction partners **6**–**12** for a Heck reaction or a cross-coupling reaction with bithiazole **4**.

We next tried to employ the Suzuki cross-coupling as an alternative C–C-bond forming reaction. Hydroboration of an alkyne with catecholborane and subsequent hydrolysis^[17] was expected to deliver an *E*-alkenyl boronic acid which could be attached to the bithiazole fragment by Pd⁰ catalysis. As the hydroborating reagent also reduces carbonyl groups the strategy required appropriate protection of ketones and aldehydes. Initial attempts with propargyl methyl ether (**9**)

Abstract in German: Die Synthese des natürlich vorkommenden Bithiazols (+)-Cystothiazol **E** (**1e**) wird ausgehend von Oxazolidinon **2** beschrieben. Sie verläuft in 10 Stufen und einer Gesamtausbeute von 37%. Schlüsselschritt der Sequenz ist eine Suzuki-Kreuzkupplung zwischen Brombithiazol **4** und der von Alkin **11** abgeleiteten (*E*)-Alkenylboronsäure (94% Ausbeute). Im Vorfeld der Synthese wurden Untersuchungen zur Kreuzkupplung von Brombithiazol **4** durchgeführt. Während Heck-Reaktionen scheiterten, waren Suzuki- und Stille-Kreuzkupplungen erfolgreich. Auf diese Weise konnten die von Alkin **11** abgeleitete Alkenylboronsäure und das Stannan **12** in die entsprechenden Alkenylbithiazole **13** (92%) und **14** (52%) umgewandelt werden. Die Stille-Kreuzkupplung zwischen Verbindung **4** und Stannan **5** erlaubte einen Zugang zu Aldehyd **21** (97% Ausbeute) und eröffnete damit einen alternativen Syntheseweg zu (+)-Cystothiazol **E** (**1e**). Aldehyd **21** wurde überdies in das Aldolprodukt **22** umgewandelt (72%), das in bekannten Synthesen der Cystothiazole **A** (**1a**) und **C** (**1c**) als Intermediat verwendet worden war. Folglich repräsentiert die Herstellung von **21** eine formale Totalsynthese dieser Cystothiazole.

were hampered by its volatility. Cross-coupling products were not observed and there were indications that the hydroboration reaction itself had not properly worked. This suspicion was confirmed when we used the more sophisticated alkyne **10** which was available from the corresponding aldol product (see below). Under a wide variety of conditions a hydroboration of this substrate with catecholborane could not be achieved. In all instances unreacted starting material was recovered almost completely. NMR spectra of crude product gave no indication for a hydroboration. Luckily, we had also employed the *tert*-butyldimethylsilyl (TBDMS) ether **11**^[18] in parallel experiments. Its hydroboration proceeded smoothly. The success of the hydroboration was proven by cross-coupling of the corresponding alkenyl boronic acid to bromobenzene. The reaction proceeded nicely following a standard protocol^[19] {[Pd(PPh₃)₄], K₂CO₃, PhH/H₂O/EtOH 5:1:1, 90 °C} in 71 % yield. 4-Bromobithiazole (**4**), however, remained inert towards a cross-coupling with the same alkenyl boronic acid under identical conditions. Since the counterion of the hydroxide base used in Suzuki cross-coupling reactions has been shown to strongly affect the velocity of the reaction^[20] we varied the base. Indeed, this variation led to a reliable and high-yielding protocol for the Suzuki cross-coupling of 4-bromobithiazoles which was also employed in the synthesis of cystothiazole E. The key to the success was the use of CsOH as the base. The reaction of compounds **11** and **4** to product **13** is depicted in Scheme 2.




Scheme 2. The two most relevant cross-coupling reactions conducted in model studies with bithiazole **4**.

A final set of experiments was directed towards a Stille cross-coupling of bithiazole **4** with appropriate stannanes. Test reactions conducted with alkenylstannane **12**^[21] and [Pd(PPh₃)₄] in *N,N*-dimethyl acetamide (DMA) did not yield the desired product. Modifications of the reaction conditions were also successful in this instance and the clean formation of alcohol **14** was observed with [PdCl₂(PPh₃)₂] in dioxane at 100 °C (Scheme 2, 52 % yield). Even more remarkably, the same conditions were applicable to the cross-coupling of stannane **5**. The implementation of the latter reaction step in route II to cystothiazoles will be discussed in one of the following sections.

Synthesis of (+)-cystothiazole E according to route I: Based on the cross-coupling of an alkenyl boronic acid with

bithiazole **4** we executed the synthesis of cystothiazole E as outlined in Scheme 1 (route I). Since we had determined the absolute configuration of the target in our preliminary work^[6] we chose the oxazolidinone **2**^[22] which is derived from (*R*)-phenylalanine to finally obtain the naturally occurring (+)-cystothiazole E. The sequence of steps is depicted in Scheme 3. Within usual limits the yields we achieved were identical to the yields previously reported for the synthesis of (–)-cystothiazole E (*ent*-**1e**). The previously reported synthesis commenced with oxazolidinone *ent*-**2** derived from (*S*)-phenylalanine.




Scheme 3. Individual steps and yields in the synthesis of (+)-cystothiazole E (**1e**) according to route I: a) i) Bu₂BOTf (1.1 equiv), Et₃NiPr₂ (1.2 equiv) in CH₂Cl₂, 0 °C, 45 min; ii) aldehyde **3** (1.35 equiv) in CH₂Cl₂, –78 → –10 °C, 1 h, 86 %; b) Me₃O⁺BF₄[–] (2.1 equiv), 1,8-bis(*N,N*-dimethylamino)naphthalene (1.4 equiv) in CH₂Cl₂, RT, 2 d, 61 %; c) LiAlH₄ (1.1 equiv) in THF, 0 °C, 2 h, quant.; d) TBAF (1.2 equiv) on silica in THF, RT, 1 h; e) TBDMSCl (1.2 equiv), imidazole (2.5 equiv) in DMF/CH₂Cl₂, RT, 1 d, quant. (two steps); f) i) catecholborane (1.5 equiv), neat, RT → 95 °C, 3 h; ii) **4** (0.3 equiv), [Pd(PPh₃)₄] (0.015 equiv), CsOH (1.2 equiv) in H₂O/EtOH/PhH, RT → 95 °C, 16 h, 94 % (relative to **4**); g) PPTS (0.5 equiv) in EtOH, 55 °C, 24 h, 82 %; h) Dess–Martin periodinane (1.2 equiv) in CH₂Cl₂, RT, 2 h, quant.; i) MeMgCl (4 equiv) in THF, RT, 1 h, 91 %; j) Dess–Martin periodinane (1.3 equiv) in CH₂Cl₂, RT, 3 h, quant.

Aldol reaction^[23] of oxazolidinone **2** with aldehyde **3** provided access to the diastereomerically pure aldol product **15** (*syn/anti* >98:2; >95 % *de*).^[24] Methylation with the Meerwein salt trimethyloxonium tetrafluoroborate in the presence of the proton sponge 1,8-bis(*N,N*-dimethylamino)-naphthalene^[25] converted the secondary alcohol into its methyl ether **16**. Attempts to employ other methylating agents (methyl iodide, dimethyl sulfate, methyl triflate) for this conversion were unsuccessful. Methylation was achieved with MeI and K₂CO₃ in refluxing acetone but partial epimerization occurred. Reduction of the *N*-acyloxazolidinone with lithium aluminium hydride yielded the primary alcohol **17** and the recoverable auxiliary. Subsequent protec-

tive group manipulations included the cleavage of the TBDMS group from intermediate **16** (tetrabutylammonium fluoride, TBAF) to liberate the free alkyne and the installation of a protective group at the hydroxy group. For the latter purpose the TBDMS group was selected. Alkyne **18** underwent a smooth hydroboration with catecholborane. After hydrolysis the intermediate alkenyl boronic acid was not isolated but directly subjected to the Suzuki cross-coupling reaction with bithiazole **4**. The reaction which was conducted in full analogy to the transformation **11** → **13** produced the desired cystothiazole precursor **19** in excellent yield (94%). As the fluoride promoted deprotection of the silyl ether in compound **19** failed (e.g. TBAF in THF at RT, TBAF on silica gel in THF at RT, or TBAF/HOAc in THF at RT) we employed acidic conditions (pyridinium *p*-toluenesulfonate, PPTS) to generate the primary alcohol **20**. Oxidation under Dess–Martin conditions^[26] yielded the corresponding aldehyde to which methyl magnesium chloride was added. The resulting secondary alcohol was obtained as a mixture of diastereoisomers (d.r. 3:1) which were not separated but oxidized directly to the desired product, (+)-cystothiazole E (**1e**). Its identity with the natural product was proven by comparison with reported NMR data. The optical rotation was positive as expected for the (3*R*,4*S*)-stereoisomer $[[\alpha]_D^{20} = +17.6$ ($c = 0.12$, CHCl_3)] and compared well with the optical rotation determined for the natural product $[[\alpha]_D^{20} = +17.8$ ($c = 0.2$, CHCl_3)].^[1a] Overall, the synthesis of cystothiazole E along route I proceeded in 10 steps and 37% yield starting from the oxazolidinone **2**.

Synthesis of cystothiazole E and formal syntheses of cystothiazoles A and C according to route II: Whereas the order of bond connection in route I was—according to Scheme 1—(*c/a*)/*b/d* we considered in a second route the linear bond connection in the order *a/b/c/d* which would enable facile access to other cystothiazoles. Key intermediate was aldehyde **21** (Scheme 4) which can be directly employed for an aldol reaction with chiral enolate equivalents and which has been previously synthesized.^[3] The synthesis of this aldehyde based on cross-coupling methodology was possible from the corresponding alcohol **14** by Swern oxidation (89% yield). Alcohol **14** was available either directly from bithiazole **4** by Stille cross-coupling (Scheme 2) or from silyl ether **13** by deprotection (TBAF in THF, RT; 78% yield). In attempts to find a shorter route to aldehyde **21** we discovered that the Stille cross-coupling reaction of β -stannyl acrolein **5** and bithiazole **4** was a facile reaction which proceeded in 97% yield. By this means, key intermediate **21** was accessible in three consecutive cross-coupling steps from 2,4-dibromothiazole in a total yield of 68%.

The aldol reaction of aldehyde **21** with the *O*-(*Z*)-boron enolate derived from *N*-propionyloxazolidinone (**2**) proceeded smoothly and yielded the known *syn*-aldol product **22** (*syn/anti* >98:2; >95% *de*).^[3] Its conversion to cystothiazole E was achieved in three steps which were not further optimized. Following the standard protocol^[27] the oxazolidinone was substituted by *N*-methoxy-*N*-methylamine in the presence of trimethylaluminum. After *O*-methylation of the secondary alcohol the intermediate Weinreb amide **23** could be directly



Scheme 4. Individual steps and yields in the synthesis of (+)-cystothiazole E (**1e**) according to route II: a) **4** (1 equiv), **5** (3 equiv), NEt_3 (2 equiv), $[\text{PdCl}_2(\text{PPh}_3)_2]$ (0.05 equiv) in dioxane, 100 °C, 16 h, 97%; b) i) Bu_2BOTf (1.2 equiv), Et_3N (1.5 equiv) in CH_2Cl_2 , 0 °C, 45 min; ii) aldehyde **21** (0.75 equiv) in CH_2Cl_2 , $-78^\circ\text{C} \rightarrow -10^\circ\text{C}$, 1 h, 86% (relative to **21**); c) i) AlMe_3 (9 equiv), $\text{HNMe}(\text{OMe})\cdot\text{HCl}$ (9 equiv) in THF, 0 °C, 30 min; ii) **22** (1 equiv) in THF, $-15^\circ\text{C} \rightarrow \text{RT}$, 1 h; d) $\text{Me}_3\text{O}^+\text{BF}_4^-$ (6.4 equiv), 1,8-bis(*N,N*-dimethylamino)naphthalene (6.4 equiv) in CH_2Cl_2 , RT, 2 d, 17% (two steps); e) MeMgCl (6.5 equiv) in $\text{Et}_2\text{O}/\text{THF}$, RT, 1 h, 95%.

converted into the desired product by nucleophilic attack with magnesium methyl chloride.^[28] Despite its linearity, route II requires less steps than route I as it completely lacks any protective group manipulations. In this respect, it is straightforward and includes only seven synthetic transformations starting from the readily available 2,4-dibromothiazole. It is, however, hampered by the low yields achieved in the methylation step (30–35%).

Intermediate **22** has been elegantly converted to cystothiazoles A and C in recent syntheses by Williams et al. (Scheme 5).^[3,29] Cystothiazole A (**1a**) was obtained in 41% yield and cystothiazole C (**1c**) in 29% yield starting from aldol product **22**.



Scheme 5. Syntheses of cystothiazole A (**1a**) and cystothiazole C (**1c**) from intermediate **22** according to Williams et al.^[3]

In view of these results, our synthesis of intermediate **22** represents a formal access to these cystothiazoles. The calculated overall yield for cystothiazole A is 20% in eleven steps and 14% for cystothiazole C in twelve steps starting from 2,4-dibromothiazole.

Conclusion

In summary, the 4-bromobithiazole (**4**) was shown to be a versatile building block for the syntheses of cystothiazoles A, C, and E. The starting material is available from 2,4-dibromothiazole in two consecutive cross-coupling reactions (70% yield). The pivotal cross-coupling at the 4-position of

4-bromobithiazole (**4**) was closely studied. The Suzuki cross-coupling with alkenyl boronic acids and the Stille cross-coupling with alkenyl stannanes proceeded well under optimized conditions. Suzuki cross-coupling of bithiazole **4** with the boronic acid derived from aldol fragment **18** (94 % yield) allowed for a convergent synthesis of cystothiazole **E** (route I). A linear but equally efficient pathway to the same target was paved by the Stille cross-coupling of bithiazole **4** and alkenyl stannane **5** (97 % yield). The aldehyde **21** thus obtained is a versatile intermediate for the synthesis of cystothiazoles. Based on the presented cross-coupling methodology other biologically active bithiazoles should be equally well accessible. Studies along these lines are currently underway in our laboratory.

Experimental Section

General: All reactions involving water-sensitive chemicals were carried out in flame-dried glassware with magnetic stirring under Ar. Tetrahydrofuran (THF) and diethyl ether (Et₂O) were distilled from potassium immediately prior to use. *N,N*-Diisopropylethylamine was distilled from calcium hydride. [Pd(PPh₃)₄]^[30] [PdCl₂(PPh₃)₂]^[31] and [Pd₂(dba)₃]^[32] and dppf^[33] were prepared according to literature procedures. All other chemicals were either commercially available or prepared according to the cited references. TLC: Merck glass sheets (0.25 mm silica gel 60, F₂₅₄), eluent given in brackets. Detection by UV or coloration with ceric ammonium molybdate (CAM). Optical rotation: Perkin–Elmer 241 MC. Melting points (uncorrected): Reichert hot bench. NMR: Bruker spectrometers ARX-200, AC-250, AC-300 and AX-500. ¹H and ¹³C NMR spectra were recorded in CDCl₃ at ambient temperature unless stated otherwise. Chemical shifts are reported relative to tetramethylsilane as internal standard or distinguished solvent signals. Apparent multiplets which occur as a result of the accidental equality of coupling constants of magnetically nonequivalent protons are marked as virtual (virt.). IR: Bruker IFS 200 or Perkin–Elmer 1600 FT-IR. MS: Varian CH7 (EI) or Finnigan MAT 8200 (EI, CI). HRMS: Finnigan MAT 8200 (EI). GC-MS: Agilent 6890 (GC system), Agilent 5973 (Mass selective detector, EI), Column: HP 5MS (30 m). Elemental analysis: Microanalytical laboratory Beller (Göttingen). Flash chromatography:^[34] Merck silica gel 60 (230–400 mesh, ca. 50 g for 1 g of material to be separated), eluent given in brackets. Eluents [Et₂O, ethyl acetate (EtOAc) and pentane (P)] were distilled prior to use.

(4S)-Benzyl-3-[5-(*tert*-butyldimethylsilyl)-(3S)-hydroxy-(2S)-methyl-4-pentynyl]-oxazolidin-2-one (ent-15):^[24] A 1 M solution of di-*n*-butylborontriflate in dichloromethane (14.0 mL, 14.0 mmol) and *N,N*-diisopropylethylamine (2.00 g, 15.5 mmol) were carefully added to a solution of the oxazolidinone *ent*-**2** (3.00 g, 12.9 mmol)^[22] in dichloromethane (30 mL) so that the temperature remained between 0 and 5 °C. After 45 min the reaction mixture was cooled to –78 °C and a solution of aldehyde **3** (2.90 g, 17.5 mmol) in dichloromethane (10 mL) was added over a period of 1 h through a syringe pump. After 1 h at –78 °C the mixture was stirred for one additional hour at –10 °C before it was quenched by successive addition of pH 7 phosphate buffer (15 mL), methanol (42 mL) and a 1:2 mixture of 30 % H₂O₂/MeOH (45 mL) keeping the temperature between 0 and 10 °C. After 1 h the mixture was concentrated in vacuo and the resultant slurry was extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/EtOAc 80:20) to afford *ent*-**15** (4.42 g, 86 %) as a white solid. *R*_f = 0.27 (P/EtOAc 80:20); m.p. 85 °C; [α]_D²⁰ = 65.8 (c = 0.40 in CH₂Cl₂); ¹H NMR (250 MHz): δ = 0.11 [s, 6H; Si(CH₃)₂], 0.93 [s, 9H; SiC(CH₃)₃], 1.43 (d, ³J = 7.1 Hz, 3H; CHCH₃), 2.81 (dd, ²J = 13.3 Hz, ³J = 9.3 Hz, 1H; PhCHH), 3.24 (dd, ²J = 13.3 Hz, ³J = 3.3 Hz, 1H; PhCHH), 3.96 (dq, ³J = 7.1 Hz, ³J = 4.4 Hz, 1H; CHCH₃), 4.19–4.23 (m, 2H; NCHCH₂O), 4.68–4.73 (m, 2H; NCHCH₂O, CHOH), 7.19–7.36 (m, 5H; CH_{ar}); ¹³C NMR (62.9 MHz): δ = –4.8 [Si(CH₃)₂], 12.3 (NCOCHCH₃), 16.4 [SiC(CH₃)₃], 26.0 [SiC(CH₃)₃], 37.7 (PhCH₂), 44.0 (NCOCH), 55.1

(PhCH₂CH), 63.7 (OCH₂CHN), 66.2 (CHOH), 88.8 (C=CSi), 104.4 (C=CSi), 127.4 (CH_{ar}), 128.9 (CH_{ar}), 129.4 (CH_{ar}), 134.9 (C_{ar}), 152.9 (OCONCO), 175.2 (OCONCO); IR (KBr): $\tilde{\nu}$ = 3494 (brs; OH), 2931 (m; CH_{ar}), 2860 (m; CH_{al}), 1801 (s), 1670 (s; C=O), 1385 (s), 1210 cm^{–1} (s); MS (CI, isobutane): *m/z* (%): 401 (4) [*M*⁺]; elemental analysis calcd (%) for C₂₂H₃₁NO₄Si (401.58): C 65.80, H 7.78; found: C 65.85, H 7.69.

(3S)-Methoxy-(2S)-methylpentencarboxylic acid-*N*-methoxy-*N*-methylamide (10): A 2 M solution of trimethylaluminum in hexane (2.25 mL, 4.50 mmol) was added at 0 °C to a slurry of *N,O*-dimethylhydroxylamine hydrochloride (439 mg, 4.50 mmol) in THF (12 mL). After 30 min the resulting solution was cooled to –15 °C and a solution of oxazolidinone *ent*-**15** (200 mg, 500 μmol) in THF (10 mL) was added. The temperature was kept at –15 °C for 1 h and at 0 °C for 1 h. After additional stirring at room temperature for 3 h the reaction was quenched by the careful addition of dichloromethane (19 mL) and a 0.5 M aqueous HCl solution (12.5 mL). The aqueous layer was extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/EtOAc 70:30) to afford the Weinreb amide (100 mg, 70 %) as a white solid. *R*_f = 0.34 (P/EtOAc 70:30); ¹H NMR (250 MHz): δ = 0.11 [s, 6H; Si(CH₃)₂], 0.94 [s, 9H; SiC(CH₃)₃], 1.36 (d, ³J = 7.0 Hz, 3H; NCOCHCH₃), 3.20 (s, 3H; NCH₃), 3.74 (s, 3H; OCH₃), 4.08–4.16 (m, 1H; NCOCHCH₃), 4.72 (virt. t, ³J ≈ 3.1 Hz, 1H; CHOH); MS (EI, 70 eV): *m/z* (%): 270 (3) [*M*⁺ – Me], 228 (100) [*M*⁺ – *t*Bu].

A solution of the obtained Weinreb amide (100 mg, 350 μmol) in dichloromethane (3 mL) was submitted to methylation by addition of proton sponge (375 mg, 1.75 mmol) and trimethyloxonium tetrafluoroborate (259 mg, 1.75 mmol). After stirring at room temperature for 2 d the resulting slurry was filtered and the solvent was removed in vacuo. The residue was purified by flash chromatography (P/EtOAc 80:20) and the desired methyl ether (51.8 mg, 51 %) was obtained as a colorless oil. *R*_f = 0.18 (P/EtOAc 80:20); [α]_D²⁰ = –78.6 (c = 0.79 in CH₂Cl₂); ¹H NMR (250 MHz): δ = 0.06 [s, 6H; Si(CH₃)₂], 0.90 [s, 9H; SiC(CH₃)₃], 1.20 (d, ³J = 6.7 Hz, 3H; NCOCHCH₃), 3.16 (s, 3H; NCH₃), 3.11–3.26 (m, 1H; NCOCHCH₃), 3.41 (s, 3H; CHOCH₃), 3.70 (s, 3H; NOCH₃), 4.08 (d, ³J = 9.2 Hz, 1H; CHOCH₃); ¹³C NMR (62.9 MHz): δ = –4.7 [Si(CH₃)₂], 14.1 (NCOCHCH₃), 16.4 [SiC(CH₃)₃], 26.0 [SiC(CH₃)₃], 32.1 (NCH₃), 41.4 (NCOCHCH₃), 56.6 (CHOCH₃), 61.5 (NOCH₃), 72.9 (CHOCH₃), 89.4 (CCSi), 104.0 (CCSi), 174.3 (NCOCHCH₃); IR (neat): $\tilde{\nu}$ = 2933 (m; CH_{al}), 2171 (w; C=C), 1666 (s; C=O), 1463 (m), 1102 cm^{–1} (m); MS (EI, 70 eV): *m/z* (%): 284 (6) [*M*⁺ – Me], 268 (4) [*M*⁺ – OMe], 242 (100) [*M*⁺ – *t*Bu]; elemental analysis calcd (%) for C₁₅H₂₉NO₃Si (299.48): C 60.16, H 9.76; found: C 60.30, H 9.89.

To cleave off the TBDMS group a solution of the obtained methyl ether (24.0 mg, 80.1 μmol) in THF (2 mL) was treated with tetrabutylammonium fluoride (TBAF) on silica (100 mg, ≈ 100 μmol). The slurry was stirred for 2 h at room temperature. After the solvent had been removed in vacuo, the residue was purified by flash chromatography (P/EtOAc 70:30) and the desired terminal alkyne **10** (14.8 mg) was obtained as a colorless oil. *R*_f = 0.48 (P/EtOAc 80:20); [α]_D²⁰ = 46.3 (c = 0.52 in CH₂Cl₂); ¹H NMR (360 MHz): δ = 1.19 (d, ³J = 7.1 Hz, 3H; NCOCHCH₃), 2.42 (d, ⁴J = 2.0 Hz, 1H; C=CH), 3.16 (s, 3H; NCH₃), 3.16–3.22 (m, 1H; NCOCHCH₃), 3.39 (s, 3H; CHOCH₃), 3.69 (s, 3H; NOCH₃), 4.05 (dd, ³J = 9.0 Hz, ⁴J = 2.0 Hz, 1H; CHOCH₃); ¹³C NMR (90 MHz): δ = 14.1 (NCOCHCH₃), 31.9 (NCH₃), 41.3 (NCOCHCH₃), 56.8 (CHOCH₃), 61.5 (NOCH₃), 72.5 (CHOCH₃), 74.4 (C=CH), 81.5 (C=CH), 174.1 (NCOCH); IR (neat): $\tilde{\nu}$ = 3242 (s, C=CH), 2939 (s, CH_{al}), 2111 (w, C=C), 1651 (s, C=O), 1462 (m), 1100 (m), 997 cm^{–1} (m); MS (EI, 70 eV): *m/z* (%): 170 (8) [*M*⁺ – Me], 125 (46) [*M*⁺ – N(CH₃)OCH₃], 69 (100) [CH(OCH₃)CCH⁺]; HRMS: *m/z* calcd for C₈H₁₂NO₃ [*M*⁺ – Me]: 170.0817, found: 170.0818.

4-[3-(*tert*-Butyldimethylsiloxy)-propenyl]-2'-isopropyl-2,4'-bithiazole (13): Catecholborane (989 mg, 8.25 mmol) was slowly added to 3-(*tert*-butyldimethylsiloxy)-1-propyne (**11**)^[18] (935 mg, 5.50 mmol) and after 5 min the temperature was raised to 70 °C for 1 h and then to 95 °C for additional 2 h. After cooling to room temperature, water (8.25 mL) was added rapidly and the resulting slurry was stirred for 1 h. Ethanol (12 mL) was added to dilute the white precipitate. The obtained solution of the boronic acid was quantitatively given to a mixture of bromobithiazole **4** (612 mg, 2.12 mmol), [Pd(PPh₃)₄] (120 mg, 106 μmol) and a 50 % (w/w) aqueous CsOH solution (953 mg, 6.36 mmol) in benzene (60 mL). The blue solution was heated to 95 °C for 16 h. After cooling to room temperature, water

(20 mL) was added and the aqueous layer was extracted with pentane (2 × 50 mL) and dichloromethane (2 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/EtOAc 98:2) to afford **13** (742 g, 92%) as a yellow oil. R_f = 0.18 (P/EtOAc 97:3); ¹H NMR (360 MHz): δ = 0.11 [s, 6H; Si(CH₃)₂], 0.94 [s, 9H; SiC(CH₃)₃], 1.43 [d, ³J = 6.9 Hz, 6H; CH(CH₃)₂], 3.36 [sept, ³J = 6.9 Hz, 1H; CH(CH₃)₂], 4.38 (d, ³J = 3.9 Hz, 2H; OCH₂), 6.60–6.75 (m, 2H; OCH₂CHCH), 7.04 (s, 1H; CH_{ar}), 7.86 (s, 1H; CH_{ar}); ¹³C NMR (90 MHz): δ = –5.2 [Si(CH₃)₂], 18.5 [SiC(CH₃)₃], 23.1 [CH(CH₃)₂], 26.0 [SiC(CH₃)₃], 33.3 [CH(CH₃)₂], 63.3 (OCH₂CHCH), 114.8 (CH_{ar}), 114.9 (CH_{ar}), 122.0 (OCH₂CHCH), 132.4 (OCH₂CHCH), 148.7 (4'-C_{ar}), 154.7 (4-C_{ar}), 162.7 (NCS-thiazole), 178.6 (NCS-*i*Pr); IR (neat): $\tilde{\nu}$ = 3102 (w; CH_{ar}), 2953 (m; CH_{al}), 1497 (m), 1255 (m), 1111 cm⁻¹ (m); MS (EI, 70 eV): m/z (%): 380 (42) [M^+], 323 (100) [M^+ – *t*Bu], 249 (63) [M^+ – OTBDMS]; elemental analysis calcd (%) for C₁₈H₂₈N₂O₂Si (380.65): C 56.80, H 7.41; found: C 56.72, H 7.36.

4-(3-Hydroxypropenyl)-2'-isopropyl-2,4'-bithiazole (14) from silyl ether 13: A 1M solution of tetrabutylammonium fluoride (TBAF) in THF (0.60 mL, 0.60 mmol) was added to a solution of silyl ether **13** (150 mg, 394 μ mol) in THF (5 mL) and the mixture was stirred for 3 h at ambient temperature. After the solvent had been removed in vacuo, the residue was purified by flash chromatography (P/Et₂O 30:70). The known compound **14**^[3] (82.0 mg, 78%) was obtained as a white solid. R_f = 0.23 (P/Et₂O 30:70); ¹H NMR (250 MHz): δ = 1.41 [d, ³J = 6.9 Hz, 6H; CH(CH₃)₂], 2.08 (brs, 1H; OH), 3.34 [sept, ³J = 6.9 Hz, 1H; CH(CH₃)₂], 4.33 (d, ³J = 4.8 Hz, 2H; OCH₂), 6.62 (d, ³J = 15.6 Hz, 1H; OCH₂CHCH), 6.75 (dt, ³J = 4.8 Hz, ³J = 15.6 Hz, 1H; OCH₂CHCH), 7.05 (s, 1H; CH_{ar}), 7.85 (s, 1H; CH_{ar}); ¹³C NMR (62.9 MHz): δ = 23.1 [CH(CH₃)₂], 33.3 [CH(CH₃)₂], 63.1 (OCH₂CHCH), 115.0 (CH_{ar}), 115.4 (CH_{ar}), 123.4 (OCH₂CHCH), 131.8 (OCH₂CHCH), 148.5 (4'-C_{ar}), 154.2 (4-C_{ar}), 162.9 (NCS-thiazole), 178.7 (NCS-*i*Pr); MS (EI, 70 eV): m/z (%): 266 (15) [M^+], 237 (100).

4-(3-Hydroxypropenyl)-2'-isopropyl-2,4'-bithiazole (14) by Stille coupling between bithiazole 4 and stannane 12: Bromobithiazole (**4**; 42.1 mg, 145 μ mol), tributylstannyl-2-propen-1-ol (**12**)^[21] (157 mg, 453 μ mol) and [PdCl₂(PPh₃)₂] (5.1 mg, 7.3 μ mol) in dioxane (8 mL) were heated to 100 °C for 16 h. After the solvent had been removed in vacuo, the residue was purified by flash chromatography (P/Et₂O 30:70). **14** (20.0 mg, 52%) was obtained as a white solid. The spectroscopic data were identical to those obtained for the deprotection product of **13**.

(4R)-Benzyl-3-[5-(tert-butylidimethylsilyl)-(3R)-hydroxy-(2R)-methyl-4-pentynyl]-oxazolidin-2-one (15): Aldol product **15** was prepared as described for its enantiomer starting from **2** (1.00 g, 4.30 mmol), di-*n*-butylborontriflate (1M in CH₂Cl₂, 4.67 mL, 4.67 mmol), *N,N*-diisopropylethylamine (667 mg, 5.17 mmol) and aldehyde **3** (967 mg, 5.83 mmol). After purification by flash chromatography (P/EtOAc 80:20) product **15** (1.47 g, 86%) could be obtained as a white solid. R_f = 0.27 (P/EtOAc 80:20); m.p. 85 °C; $[\alpha]_D^{20}$ = –66.1 (c = 0.53 in CH₂Cl₂). The spectroscopic data were identical to those of *ent*-**15**.

(4R)-Benzyl-3-[5-(tert-butylidimethylsilyl)-(3R)-methoxy-(2R)-methyl-4-pentynyl]-oxazolidin-2-on (16): Proton sponge (3.34 g, 15.6 mmol) and trimethyloxonium tetrafluoroborate (3.50 g, 23.4 mmol) were added to a solution of the alcohol **15** (4.50 g, 11.1 mmol) in dichloromethane (80 mL). After stirring at room temperature for 2 d the resultant slurry was filtered and the solvent was removed in vacuo. The residue was purified by flash chromatography (P/EtOAc 90:10) and the desired methyl ether **16** (2.79 g, 61%) was obtained as a white solid. R_f = 0.57 (P/EtOAc 80:20); m.p. 135 °C; $[\alpha]_D^{20}$ = –34.2 (c = 0.61 in CH₂Cl₂); ¹H NMR (250 MHz): δ = 0.10 [s, 6H; Si(CH₃)₂], 0.92 [s, 9H; SiC(CH₃)₃], 1.35 (d, ³J = 6.4 Hz, 3H; NCOCHCH₃), 2.79 (dd, ²J = 16.0 Hz, ³J = 9.6 Hz, 1H; PhCHH), 3.28 (dd, ²J = 16.0 Hz, ³J = 3.1 Hz, 1H; PhCHH), 3.42 (s, 3H; CHOCH₃), 4.14–4.25 (m, 4H; CH₃CHCHOCH₃, NCHCH₂O), 4.64–4.69 (m, 1H; NCHCH₂O), 7.19–7.29 (m, 5H; CH_{ar}); ¹³C NMR (62.9 MHz): δ = –4.3 [Si(CH₃)₂], 13.9 (NCOCHCH₃), 16.9 [SiC(CH₃)₃], 26.4 [SiC(CH₃)₃], 38.2 (PhCH₂), 43.3 (NCOCH), 55.8 (OCH₂CHN), 56.8 (CHOCH₃), 66.5 (OCH₂CHN), 72.7 (CHOCH₃), 87.5 (C=CSi), 90.6 (C=CSi), 127.7 (CH_{ar}), 129.3 (CH_{ar}), 129.8 (CH_{ar}), 135.6 (C_{ar}), 153.4 (OCONCO), 173.9 (OCONCO); IR (KBr): $\tilde{\nu}$ = 2934 (m; CH_{al}), 1769 (s; C=O), 1684 (s; C=O), 1384 (m), 1208 cm⁻¹ (m); MS (EI, 70 eV): m/z (%): 415 (2) [M^+], 400 (5) [M^+ – Me], 358 (100) [M^+ – *t*Bu]; elemental analysis calcd (%) for C₂₃H₃₃NO₄Si (415.60): C 66.47, H 8.00; found: C 66.41, H 7.95.

5-(tert-Butyldimethylsilyl)-(3R)-methoxy-(2S)-methyl-4-pentyn-1-ol (17): A solution of oxazolidinone **16** (2.67 g, 6.43 mmol) in THF (40 mL) was added at 0 °C to a slurry of lithium aluminium hydride (268 mg, 7.10 mmol) in THF (100 mL) over a period of 1 h through syringe pump. After stirring for 1 h at 0 °C, water (267 μ L), 15% aqueous NaOH (800 μ L), water (800 μ L) and some Na₂SO₄ were successively added. The mixture was filtered, the solvent was removed in vacuo and the resulting residue was purified by flash chromatography (P/EtOAc 70:30). **17** (1.56 g, quant.) was obtained as a light red oil. R_f = 0.33 (P/EtOAc 85:15); $[\alpha]_D^{20}$ = –71.2 (c = 1.10 in CH₂Cl₂); ¹H NMR (360 MHz): δ = 0.11 [s, 6H; Si(CH₃)₂], 0.93 [s, 9H; SiC(CH₃)₃], 0.95 (d, ³J = 7.5 Hz, 3H; CHCH₃), 2.06–2.14 (m, 1H; CHCH₃), 3.40 (s, 3H; CHOCH₃), 3.55 (dd, ²J = 10.9 Hz, ³J = 3.8 Hz, 1H; HOCHH), 3.80 (dd, ²J = 10.9 Hz, ³J = 7.5 Hz; HOCHH), 4.07 (d, ³J = 4.0 Hz, 1H; CHOCH₃); ¹³C NMR (90 MHz): δ = –4.6 [Si(CH₃)₂], 12.7 [CH(CH₃)], 16.5 [SiC(CH₃)₃], 26.1 [SiC(CH₃)₃], 39.7 [CH(CH₃)], 56.9 (CHOCH₃), 65.6 (HOCH₂), 76.1 (CHOCH₃), 91.1 (CCSi), 102.8 (CCSi); IR (neat): $\tilde{\nu}$ = 3373 (b; OH), 2929 (s; CH_{al}), 2857 (s; CH_{al}), 2169 (m; C=C), 1471 (s), 1250 (s), 1096 cm⁻¹ (s); MS (CI, isobutane): m/z (%): 243 (6) [M^+ + H].

1-tert-Butyldimethylsiloxy-(3R)-methoxy-(2R)-methyl-4-pentyne (18): To cleave off the TBDMS group a solution of alcohol **17** (1.00 g, 4.13 mmol) in THF (40 mL) was treated with tetrabutylammonium fluoride (TBAF) on silica (5.00 g, $\approx$ 5.00 mmol). The slurry was stirred for 1 h at room temperature. After the solvent had been removed in vacuo, the residue was purified by flash chromatography (P/Et₂O 50:50) and the desired terminal alkyne (529 mg, quant.) was obtained as a colourless oil. R_f = 0.52 (P/EtOAc 50:50). The resulting alcohol was diluted in DMF (35 mL). Dichloromethane (15 mL), imidazole (703 mg, 10.3 mmol) and a 2.9M solution of *tert*-butyldimethylsilylchloride in toluene (1.71 mL, 4.96 mmol) were added. After stirring for 1 d at room temperature, water (100 mL) was added and the aqueous layer was extracted with dichloromethane (2 × 150 mL) and pentane (2 × 150 mL). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/Et₂O 98:2) to afford **18** (1.00 g, quant.) as a colorless oil. R_f = 0.67 (P/Et₂O 95:5); $[\alpha]_D^{20}$ = 53.9 (c = 0.54 in pentane); ¹H NMR (250 MHz): δ = 0.02 [s, 6H; Si(CH₃)₂], 0.87 [s, 9H; SiC(CH₃)₃], 0.97 (d, ³J = 7.0 Hz, 3H; CHCH₃), 1.84–1.97 (m, 1H; CHCH₃), 2.40 (d, ⁴J = 2.1 Hz, 1H; C=CH), 3.38 (s, 3H; CHOCH₃), 3.52 (dd, ²J = 9.8 Hz, 1H; SiOCHH), 3.61 (dd, ²J = 9.8 Hz, ³J = 5.8 Hz, 1H; SiOCHH), 4.04 (dd, ³J = 4.6 Hz, ⁴J = 2.1 Hz, 1H; CHOCH₃); ¹³C NMR (62.9 MHz): δ = –5.5 [Si(CH₃)₂], 11.6 [CH(CH₃)], 18.3 [SiC(CH₃)₃], 25.9 [SiC(CH₃)₃], 41.0 [CH(CH₃)], 57.0 (CHOCH₃), 65.2 (SiOCH₂), 71.6 (C=CH), 74.1 (CHOCH₃), 82.2 (C=CH); IR (neat): $\tilde{\nu}$ = 2929 (m; CH_{al}), 2858 (m; CH_{al}), 1472 (m), 1258 cm⁻¹ (s); MS (CI, isobutane): m/z (%): 243 (100) [M^+ + H].

4-[5-(tert-Butyldimethylsiloxy)-(3S)-methoxy-(4R)-methylpent-1-enyl]-2'-isopropyl-2,4'-bithiazole (19): Catecholborane (673 mg, 5.60 mmol) was slowly added to alkyne **18** (905 mg, 3.74 mmol) and after 5 min the temperature was raised to 70 °C for 1 h and then to 95 °C for further 2 h. After cooling to room temperature, water (7.5 mL) was added rapidly and the resulting slurry was stirred for 1 h. Ethanol (12 mL) was added to dilute the white precipitate. The obtained solution of the boronic acid was quantitatively given to a mixture of bromobithiazole **4** (314 mg, 1.10 mmol), [Pd(PPh₃)₄] (87.0 mg, 55.0 μ mol) and a 10% (w/w) aqueous CsOH solution (7.50 mL, 4.50 mmol) in benzene (70 mL). This blue solution was heated to 95 °C for 16 h. After cooling to room temperature, water (40 mL) was added and the aqueous layer was extracted with pentane (2 × 100 mL) and dichloromethane (2 × 100 mL). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/Et₂O 95:5) to afford **19** (448 g, 94%) as a yellow oil. R_f = 0.35 (P/EtOAc 90:10); $[\alpha]_D^{20}$ = 8.9 (c = 0.40 in pentane); ¹H NMR (250 MHz): δ = 0.02 [s, 6H; Si(CH₃)₂], 0.88 [s, 9H; SiC(CH₃)₃], 0.92 (d, ³J = 6.2 Hz, 3H; SiOCH₂CHCH₃), 1.41 [d, ³J = 6.9 Hz, 6H; CH(CH₃)₂], 1.77–1.87 (m, 1H; SiOCH₂CHCH₃), 3.31 (s, 3H; CHOCH₃), 3.33 [sept, ³J = 6.9 Hz, 1H; CH(CH₃)₂], 3.48 (dd, ²J = 9.7 Hz, ³J = 5.7 Hz, 1H; SiOCHH), 3.60 (dd, ²J = 9.7 Hz, ³J = 6.7 Hz, 1H; SiOCHH), 3.85 (virt. t, ³J $\approx$ 5.0 Hz, 1H; CHOCH₃), 6.45–6.61 (m, 2H; CH₃OCHCHCH), 7.05 (s, 1H; CH_{ar}), 7.84 (s, 1H; CH_{ar}); ¹³C NMR (62.9 MHz): δ = –5.5 [Si(CH₃)₂], 11.6 (SiOCH₂CHCH₃), 18.2 [SiC(CH₃)₃], 23.1 [CH(CH₃)₂], 25.9 [SiC(CH₃)₃], 33.3 [CH(CH₃)₂], 41.0 (SiOCH₂CH), 57.1 (CHOCH₃), 64.8 (SiOCH₂), 82.1

(CHOCH₃), 114.9 (CH'_{ar}), 115.0 (CH_{ar}), 124.8 (CH₃OCHCHCH), 132.2 (CH₃OCHCHCH), 148.7 (4'-C_{ar}), 154.4 (4-C_{ar}), 162.7 (NCS-thiazole), 178.6 (NCS-*i*Pr); IR (neat): $\tilde{\nu}$ = 3110 (w; CH_{ar}), 2928 (m; CH_{al}), 2856 (m; CH_{al}), 1463 (s), 1255 cm⁻¹ (s); MS (EI, 70 eV): m/z (%): 452 (12) [M^+], 437 (8) [M^+ – Me], 395 (50) [M^+ – *t*Bu], 305 (41), 289 (27), 279 (100) [M^+ – TBDMSOCH₂CH(Me)]; HRMS: m/z calcd for C₂₂H₃₆N₂O₂Si: 452.1988, found: 452.1982.

5-(2'-Isopropyl-2,4'-bithiazolyl-4-yl)-(3S)-methoxy-(2S)-methyl-4-penten-1-ol (20): Silyl ether **19** (410 mg, 905 μ mol) and pyridinium *para*-toluenesulfonate (PPTS) (116 mg, 450 μ mol) in ethanol (20 mL) were heated to 55 °C for 24 h. After removal of the solvent the residue was purified by flash chromatography (P/Et₂O 50:50). **20** (250 mg, 82%) was obtained as a colourless oil. R_f = 0.28 (P/Et₂O 30:70); [α]_D²⁰ = 41.9 (c = 0.83 in diethyl ether); ¹H NMR (250 MHz): δ = 0.93 (d, ³ J = 7.0 Hz, 3H; HOCH₂CHCH₃), 1.42 [d, ³ J = 7.0 Hz, 6H; CH(CH₃)₂], 2.05–2.11 (m, 1H; HOCH₂CHCH₃), 3.33 (s, 3H; CHOCH₃), 3.34 [sept, ³ J = 7.0 Hz, 1H; CH(CH₃)₂], 3.58 (dd, ² J = 10.8 Hz, ³ J = 4.3 Hz, 1H; HOCHH), 3.73 (dd, ² J = 10.8 Hz, ³ J = 7.5 Hz, 1H; HOCHH), 3.90 (virt. t, ³ J $\approx$ 4.9 Hz, 1H; CHOCH₃), 6.50–6.65 (m, 2H; CH₃OCHCHCH), 7.10 (s, 1H; CH_{ar}), 7.89 (s, 1H; CH_{ar}); ¹³C NMR (62.9 MHz): δ = 12.2 (HOCH₂CHCH₃), 23.1 [CH(CH₃)₂], 33.3 [CH(CH₃)₂], 39.8 (HOCH₂CH), 57.0 (CHOCH₃), 66.0 (HOCH₂), 85.6 (CHOCH₃), 115.3 (CH'_{ar}), 115.7 (CH_{ar}), 126.1 (CH₃OCHCHCH), 130.0 (CH₃OCHCHCH), 148.4 (4'-C_{ar}), 153.8 (4-C_{ar}), 163.0 (NCS-thiazole), 178.7 (NCS-*i*Pr); IR (neat): $\tilde{\nu}$ = 3420 (brs; OH), 3122 (w; CH_{ar}), 2971 (s; CH_{al}), 1498 (m), 1081 cm⁻¹ (s); MS (EI, 70 eV): m/z (%): 338 (10) [M^+], 323 (13) [M^+ – Me], 279 (100) [M^+ – HOCH₂CHMe]; elemental analysis calcd (%) for C₁₆H₂₂N₂O₂S₂ (338.49): C 56.77, H 6.55; found: C 57.01, H 6.66.

(+)-Cystothiazole E (1e): Dess–Martin periodinane^[26] (93.1 mg, 220 μ mol) was added to a solution of alcohol **20** (62.0 mg, 183 μ mol) in dichloromethane (2 mL). After being stirred at ambient temperature for 2 h, the reaction was quenched by the addition of diethyl ether (12 mL) and a saturated aqueous solution of NaHCO₃ containing 5% Na₂S₂O₃ (4 mL). After additional 15 min the aqueous phase was extracted with diethyl ether (2 $\times$ 20 mL). The combined organic phases were washed with brine (10 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/Et₂O 60:40) to afford the desired aldehyde (61.0 mg, quant.) as a yellow oil. R_f = 0.39 (P/Et₂O 50:50); ¹H NMR (250 MHz): δ = 1.18 (d, ³ J = 7.0 Hz, 3H; OHCHCHCH₃), 1.44 [d, ³ J = 6.9 Hz, 6H; CH(CH₃)₂], 2.62–2.67 (m, 1H; OHCHCHCH₃), 3.35 [sept, ³ J = 6.9 Hz, 1H; CH(CH₃)₂], 3.36 (s, 3H; CHOCH₃), 4.19 (dd, ³ J = 4.3 Hz, ³ J = 7.0 Hz, 1H; CHOCH₃), 6.53 (dd, ³ J = 7.0 Hz, ³ J = 15.6 Hz, 1H; CH₃OCHCHCH), 6.67 (d, ³ J = 15.6 Hz, 1H; CH₃OCHCHCH), 7.14 (s, 1H; CH_{ar}), 7.88 (s, 1H; CH'_{ar}), 9.82 (d, ³ J = 1.2 Hz, 1H; OHCHCHCH₃); ¹³C NMR (62.9 MHz): δ = 8.7 (OHCHCHCH₃), 23.1 [CH(CH₃)₂], 33.3 [CH(CH₃)₂], 51.1 (OHCHCHCH₃), 57.0 (CHOCH₃), 81.5 (CHOCH₃), 115.1 (CH'_{ar}), 116.2 (CH_{ar}), 126.4 (CH₃OCHCHCH), 129.4 (CH₃OCHCHCH), 148.5 (4'-C_{ar}), 153.6 (4-C_{ar}), 163.0 (NCS-thiazole), 178.7 (NCS-*i*Pr), 203.8 (OHCHCHCH₃); IR (neat): $\tilde{\nu}$ = 3215 (m; CH_{ar}), 2969 (m; CH_{al}), 1727 (s; C=O), 1617 (s), 1079 cm⁻¹ (s); MS (EI, 70 eV): m/z (%): 336 (4) [M^+], 321 (4) [M^+ – Me], 279 (100) [M^+ – OHCHCHMe].

To a solution of the aldehyde (61.0 mg, 182 μ mol) in THF (5 mL) a 3M solution of methyl magnesium chloride in THF (242 μ L, 726 μ mol) was added at room temperature. After stirring for 1 h, a saturated aqueous solution of NH₄Cl (5 mL) was added. The aqueous phase was extracted with diethyl ether (3 $\times$ 20 mL). The combined organic phases were washed with brine (15 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/Et₂O 60:40) to afford the desired secondary alcohol (58.2 mg, 91%) as a yellow oil. It was obtained as a 3:1 mixture of diastereoisomers. R_f = 0.15 and 0.18 (P/Et₂O 50:50); ¹³C NMR (62.9 MHz): *major* diastereoisomer: δ = 12.8 (HOCHCHCH₃), 20.9 (CH₃CHOH), 23.1 [CH(CH₃)₂], 43.7 (HOCHCHCH₃), 56.8 (OCH₃), 70.8 (HOCH), 86.9 (CHOCH₃), 115.0 (CH'_{ar}), 115.7 (CH'_{ar}), 125.2 (CH₃OCHCHCH), 131.1 (CH₃OCHCHCH), 148.4 (4'-C_{ar}), 153.9 (4-C_{ar}), 162.9 (NCS-thiazole), 178.6 (NCS-*i*Pr); *minor* diastereoisomer: δ = 15.2 (HOCHCHCH₃), 21.5 (CH₃CHOH), 23.1 [CH(CH₃)₂], 44.1 (HOCHCHCH₃), 56.9 (OCH₃), 69.8 (HOCH), 85.5 (CHOCH₃), 115.0 (CH'_{ar}), 115.6 (CH'_{ar}), 126.3 (CH₃OCHCHCH), 129.4 (CH₃OCHCHCH), 148.4 (4'-C_{ar}), 153.8 (4-C_{ar}), 162.8 (NCS-thiazole), 178.6 (NCS-*i*Pr); IR (KBr): $\tilde{\nu}$ = 3440 (brs; OH), 3124 (m; CH_{ar}), 2970 (s; CH_{al}), 1498 cm⁻¹ (s); MS (EI, 70 eV): m/z (%): 352 (8) [M^+], 337 (6) [M^+ – Me],

279 (84) [M^+ – MeCH(OH)CH(Me)], 261 (100); HRMS: m/z calcd for C₁₇H₂₄N₂O₂S₂: 352.1279, found: 352.1282.

The mixture of alcohols (48.0 mg, 137 μ mol) was dissolved in dichloromethane (5 mL) and the Dess–Martin periodinane (76.3 mg, 180 μ mol) was added. After being stirred at ambient temperature for 3 h, the reaction was quenched by the addition of diethyl ether (20 mL) and a saturated aqueous solution of NaHCO₃ containing 5% Na₂S₂O₃ (6 mL). After further 15 min the aqueous phase was extracted with diethyl ether (2 $\times$ 20 mL). The combined organic phases were washed with brine (20 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/Et₂O 70:30) to afford (+)-cystothiazole **E (1e)** (48.0 mg, quant.) as a yellow oil. R_f = 0.65 (P/Et₂O 50:50); [α]_D²⁰ = 17.6 (c = 0.12 in CHCl₃); ¹H NMR (360 MHz): δ = 1.19 (d, ³ J = 7.0 Hz, 3H; CH₃COCHCH₃), 1.44 [d, ³ J = 7.0 Hz, 6H; CH(CH₃)₂], 2.20 (s, 3H; CH₃CO), 2.79 (virt. quin, ³ J $\approx$ 6.5 Hz, 1H; CH₃COCH), 3.34 (s, 3H; CHOCH₃), 3.37 [sept, ³ J = 7.0 Hz, 1H; CH(CH₃)₂], 4.02 (virt. t, ³ J $\approx$ 6.6 Hz, 1H; CHOCH₃), 6.46 (dd, ³ J = 7.2 Hz, ³ J = 15.8 Hz, 1H; CH₃OCHCHCH), 6.61 (d, ³ J = 15.8 Hz, 1H; CH₃OCHCHCH), 7.11 (s, 1H; H_{ar}), 7.87 (s, 1H; H'_{ar}); ¹³C NMR (90 MHz): δ = 11.8 (CH₃COCHCH₃), 23.0 [CH(CH₃)₂], 29.8 (CH₃COCHCH₃), 33.3 [CH(CH₃)₂], 51.9 (CH₃COCHCH₃), 56.9 (CHOCH₃), 82.6 (CHOCH₃), 115.0 (5'-CH_{ar}), 115.7 (5-CH_{ar}), 126.1 (CH₃OCHCHCH), 130.1 (CH₃OCHCHCH), 148.5 (4'-C_{ar}), 153.8 (4-C_{ar}), 162.8 (NCS-thiazole), 178.5 (NCS-*i*Pr), 210.3 (CH₃CO); IR (neat): $\tilde{\nu}$ = 3103 (m; CH_{ar}), 2970 (s; CH_{al}), 2932 (s; CH_{al}), 1712 cm⁻¹ (s; C=O); MS (EI, 70 eV): m/z (%): 350 (2) [M^+], 335 (12) [M^+ – Me], 279 (89) [M^+ – MeCOCHMe], 275 (100); elemental analysis calcd (%) for C₁₇H₂₃N₂O₂S₂ (350.50): C 58.25, H 6.33; found: C 58.06, H 6.13.

3-(2'-Isopropyl-2,4'-bithiazolyl-4-yl)-propenal (21): Bromobithiazole **4** (217 mg, 751 μ mol), tributylstannyl-2-propen-1-ol (**5**)^[8] (777 mg, 2.25 mmol) triethylamine (152 mg, 1.50 mmol) and [PdCl₂(PPh₃)₂] (26.4 mg, 37.6 μ mol) in dioxane (40 mL) were heated at 100 °C for 16 h. After the solvent had been removed in vacuo, the residue was purified by flash chromatography (P/Et₂O 70:30). The known aldehyde **21**^[3] (192 mg, 97%) was obtained as a yellow solid. R_f = 0.48 (P/EtOAc 75:25); ¹H NMR (250 MHz): δ = 1.42 [d, ³ J = 7.0 Hz, 6H; CH(CH₃)₂], 3.34 [sept, ³ J = 7.0 Hz, 1H; CH(CH₃)₂], 7.05 (dd, ³ J = 7.9 Hz, ³ J = 15.6 Hz, 1H; OHCHCHCH), 7.42 (d, ³ J = 15.6 Hz, 1H; OHCHCHCH), 7.55 (s, 1H; CH_{ar}), 7.88 (s, 1H; CH'_{ar}), 9.71 (d, ³ J = 7.9 Hz, 1H; OHCHCHCH); ¹³C NMR (62.9 MHz): δ = 23.1 [CH(CH₃)₂], 33.3 [CH(CH₃)₂], 116.0 (CH'_{ar}), 123.4 (CH_{ar}), 130.5 (OHCHCHCH), 143.6 (OHCHCHCH), 147.9 (4'-C_{ar}), 152.2 (4-C_{ar}), 163.9 (NCS-thiazole), 178.9 (NCS-*i*Pr), 193.6 (OHCHCHCH); MS (EI, 70 eV): m/z (%): 264 (64) [M^+], 236 (100) [M^+ – CO], 221 (95) [M^+ – *i*Pr].

(4R)-Benzyl-3-[(3S)-hydroxy-5-(2'-isopropyl-2,4'-bithiazolyl-4-yl)-(2R)-methyl-4-pentenoyl]-oxazolidin-2-one (22): A 1M solution of di-*n*-butylborontriflate in dichloromethane (370 μ L, 370 μ mol) and *N,N*-diisopropylethylamine (61.5 mg, 476 μ mol) were carefully added to a solution of the oxazolidinone **2** (74.0 mg, 318 μ mol) in dichloromethane (4 mL) so that the temperature was between 0 and 5 °C. After 45 min the reaction mixture was cooled to –78 °C and a solution of aldehyde **21** (64.0 mg, 242 μ mol) in dichloromethane (2 mL) was added over a period of 1 h through syringe pump. After 1 h the mixture was stirred for 2 h at 0 °C before it was quenched by successive addition of pH 7 phosphate buffer (1 mL), methanol (2 mL) and a 1:2 mixture of 30% H₂O₂/MeOH (2 mL) keeping the temperature between 0 and 10 °C. After 1 h the mixture was concentrated in vacuo and the resulting slurry was extracted with EtOAc (3 $\times$ 50 mL). The combined organic phases were washed with brine (30 mL), dried over Na₂SO₄ and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/EtOAc 60:40) to afford the known aldol product **22**^[3] (87.0 mg, 72%) as a white foam. R_f = 0.33 (P/EtOAc 50:50); ¹³C NMR (90 MHz): δ = 11.2 (NCOCHCH₃), 23.1 [CH(CH₃)₂], 33.2 [CH(CH₃)₂], 37.6 (PhCH₂), 42.6 (NCOCHCH₃), 55.1 (PhCH₂CH), 66.1 (PhCH₂CHCH₂), 71.9 (CHOH), 115.2 (CH_{ar}), 115.9 (CH_{ar}), 123.9 (HOCHCHCH), 127.3 (CH_{ph}), 128.9 (CH_{ph}), 129.4 (CH_{ph}), 131.7 (HOCHCHCH), 134.9 (C_{ph}), 148.3 (4'-C_{ar}), 153.0 (OCONCO), 153.9 (4-C_{ar}), 162.8 (NCS-thiazole), 176.6 (OCONCO), 178.7 (NCS-*i*Pr).

5-(2'-Isopropyl-2,4'-bithiazolyl-4-yl)-(3S)-methoxy-(2R)-methylpent-4-encarboxylic acid-*N*-methoxy-*N*-methylamide (23): A 2M solution of trimethylaluminum in hexane (0.79 mL, 1.58 mmol) was added at 0 °C to a slurry of *N,O*-dimethylhydroxylamine hydrochloride (154 mg, 1.58 mmol) in THF (5 mL). After 30 min the resulting solution was cooled to –15 °C and a solution of aldol product **22** (87.0 mg, 175 μ mol) in THF (5 mL) was added.

The temperature was kept at -15°C , 0°C and ambient temperature for 1 h. The reaction was stopped by the careful addition of a 0.5 M aqueous HCl solution (4 mL) at 0°C . The aqueous phase was extracted with dichloromethane (2×15 mL). The combined organic phases were washed with brine (10 mL), dried over Na_2SO_4 and filtered. After removal of the solvent the crude residue was purified by flash chromatography (P/EtOAc 40:60) to afford a mixture (85.0 mg) of the Weinreb amide and the Evans auxiliary as a yellow oil which still contained some EtOAc. $R_f = 0.18$ (P/EtOAc 50:50); ^1H NMR (360 MHz): $\delta = 1.22$ (d, $^3J = 7.3$ Hz, 3H; NCOCHCH_3), 1.44 [d, $^3J = 6.9$ Hz, 6H; $\text{CH}(\text{CH}_3)_2$], 2.87 (m, 1H; NCOCHCH_3), 3.22 (s, 3H; NCH_3), 3.38 [sept, $^3J = 6.9$ Hz, 1H; $\text{CH}(\text{CH}_3)_2$], 3.73 (s, 3H; OCH_3), 4.12 (m, 1H; CHOH), 6.62 (dd, $^3J = 4.6$ Hz, $^3J = 15.4$ Hz, 1H; HOCHCHCH), 6.76 (d, $^3J = 15.4$ Hz, 1H; HOCHCHCH), 7.09 (s, 1H; CH_{ar}), 7.87 (s, 1H; CH_{ar}); ^{13}C NMR (90 MHz): $\delta = 10.4$ (NCOCHCH_3), 23.0 [$\text{CH}(\text{CH}_3)_2$], 31.7 (CH_3NCO), 33.2 [$\text{CH}(\text{CH}_3)_2$], 38.9 (NCOCHCH_3), 61.6 (H_3CONCH_3), 71.3 (CHOH), 114.9 (CH_{ar}), 115.6 (CH_{ar}), 123.3 (HOCHCHCH), 131.9 (HOCHCHCH), 148.4 (4-C_{ar}), 154.1 (4-C_{ar}), 162.6 (NCS-thiazole), 177.6 (H_3CNCO), 178.6 (NCS-*i*Pr).

Proton sponge (240 mg, 1.12 mmol) and trimethyloxonium tetrafluoroborate (166 mg, 1.12 mmol) were added to a solution of the above mixture (85 mg) in dichloromethane (5 mL). After stirring at room temperature for 2 d the resulting slurry was filtered and the solvent was removed in vacuo. The residue was purified by flash chromatography (P/EtOAc 50:50) and the desired methyl ether **23** (12.0 mg, 17 %) was obtained as a yellow oil. $R_f = 0.37$ (P/EtOAc 50:50); $[\alpha]_D^{20} = 20.0$ ($c = 0.13$ in diethyl ether); ^1H NMR (250 MHz): $\delta = 1.23$ (d, $^3J = 7.3$ Hz, 3H; NCOCHCH_3), 1.42 [d, $^3J = 6.9$ Hz, 6H; $\text{CH}(\text{CH}_3)_2$], 3.11 (s, 3H; NCH_3), 3.16 (m, 1H; NCOCHCH_3), 3.31 (s, 3H; CHOCH_3), 3.34 [sept, $^3J = 6.9$ Hz, 1H; $\text{CH}(\text{CH}_3)_2$], 3.64 (s, 3H; CH_3NOCH_3), 3.86 (m, 1H; CHOCH_3), 6.48 (dd, $^3J = 4.6$ Hz, $^3J = 15.4$ Hz, 1H; $\text{CH}_3\text{OCHCHCH}$), 6.72 (d, $^3J = 15.4$ Hz, 1H; $\text{CH}_3\text{OCHCHCH}$), 7.09 (s, 1H; CH_{ar}), 7.84 (s, 1H; CH_{ar}); ^{13}C NMR (62.9 MHz): $\delta = 14.2$ (NCOCHCH_3), 23.1 [$\text{CH}(\text{CH}_3)_2$], 32.3 (H_3CONCH_3), 33.3 [$\text{CH}(\text{CH}_3)_2$], 41.1 (NCOCHCH_3), 57.1 (CHOCH_3), 61.5 (H_3CONCH_3), 83.7 (CHOCH_3), 115.0 (CH_{ar}), 115.6 (CH_{ar}), 126.0 ($\text{CH}_3\text{OCHCHCH}$), 131.2 ($\text{CH}_3\text{OCHCHCH}$), 148.6 (4-C_{ar}), 154.1 (4-C_{ar}), 162.6 (NCS-thiazole), 177.6 (H_3CNCO), 178.6 (NCS-*i*Pr); IR (neat): $\tilde{\nu} = 3102$ (m; CH_{ar}), 2969 (m; CH_{ar}), 1654 (s; C=O), 1458 (m), 1181 (m), 1094 cm^{-1} (s); MS (EI, 70 eV): m/z (%): 395 (24) [M^+], 380 (16) [$M^+ - \text{Me}$], 279 (100) [$M^+ - \text{MeON}(\text{Me})\text{COCHMe}$]; HRMS: m/z calcd for $\text{C}_{18}\text{H}_{25}\text{N}_3\text{O}_3\text{S}_2$: 395.1337, found: 395.1339.

Cystothiazole E (1e): A 3 M solution of methyl magnesium chloride in THF (50.0 μL , 150 μmol) was added to a solution of the Weinreb amide **23** (9.0 mg, 23.0 μmol) in diethyl ether (2 mL) at 0°C . After stirring at 0°C for 1 h, a saturated aqueous solution of NH_4Cl (2 mL) was added and the aqueous layer was extracted with diethyl ether (3×20 mL). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 and filtered. The solvent was removed in vacuo to yield pure (+)-cystothiazole **E (1e)** (8.0 mg, 95 %) as a yellow oil. The spectroscopical data were identical with those determined for the product obtained according to route I and with those reported for the natural product.

Acknowledgements

This project was supported by the Deutsche Forschungsgemeinschaft (Ba 1372/5-2) and by the Fonds der Chemischen Industrie. We would like to thank Sven Schröter and Andreas Suppan (undergraduate research participants) for skillful technical assistance. The donation of chemicals by OMG AG (Hanau-Wolfgang) and by Wacker-Chemie (München) is gratefully acknowledged.

- [1] a) Y. Suzuki, M. Ojika, Y. Sakagami, R. Fudou, S. Yamanaka, *Tetrahedron* **1998**, *54*, 11399–11404; b) Y. Suzuki, M. Ojika, Y. Sakagami, R. Fudou, S. Yamanaka, A. Tsukamoto, T. Yoshimura, *J. Antibiot.* **1998**, *51*, 275–281.
[2] a) T. Anke, F. Oberwinkler, W. Steglich, G. Schramm, *J. Antibiot.* **1977**, *30*, 806–810; b) T. Anke, H. J. Hecht, G. Schramm, W. Steglich, *J.*

- Antibiot.* **1979**, *32*, 1112–1117; c) W. Trowitzsch-Kienast, V. Wray, K. Gerth, H. Reichenbach, G. Höfle, *Liebigs Ann. Chem.* **1986**, 93–98; d) H. Sauter, T. Anke, W. Steglich, *Angew. Chem.* **1999**, *111*, 1416–1438; *Angew. Chem. Int. Ed.* **1999**, *38*, 1328–1349.
[3] D. R. Williams, S. Patnaik, M. P. Clark, *J. Org. Chem.* **2001**, *66*, 8463–8469.
[4] K. Kato, A. Nishimura, Y. Yamamoto, H. Akita, *Tetrahedron Lett.* **2002**, *43*, 643–645.
[5] M. Sui, J. S. Panek, *Org. Lett.* **2001**, *3*, 2439–2442.
[6] T. Bach, S. Heuser, *Angew. Chem.* **2001**, *113*, 3283–3284; *Angew. Chem. Int. Ed.* **2001**, *40*, 3184–3185.
[7] T. Bach, S. Heuser, *J. Org. Chem.* **2002**, *67*, 5789–5795.
[8] H. Oda, T. Kobayashi, M. Kosugi, T. Migita, *Tetrahedron* **1995**, *51*, 695–702.
[9] S. Heuser, Diplomarbeit, Universität Marburg (Germany), **1999**.
[10] For a successful Negishi cross-coupling, see: S.-T. Huang, D. M. Gordon, *Tetrahedron Lett.* **1998**, *39*, 9335–9338.
[11] T. Bach, S. Heuser, *Tetrahedron Lett.* **2000**, *41*, 1707–1710.
[12] For references on cross-coupling reactions of heterocycles, see: a) J. J. Li, G. Gribble, *Palladium in Heterocyclic Chemistry*, Pergamon Press, Oxford, **2000**; b) L. Brandsma, S. F. Vasilevsky, H. D. Verkruijsse, *Application of Transition Metal Catalysts in Organic Synthesis*, Springer, Berlin, **1999**; c) F. Diederich, P. J. Stang, *Metal-Catalyzed Cross-coupling Reactions*, Wiley-VCH, Weinheim, **1998**.
[13] A. Dondoni, M. Faganolo, A. Medici, E. Negrini, *Synthesis* **1987**, 185–186.
[14] a) T. Sakamoto, H. Nagata, Y. Kondo, M. Shiraiwa, H. Yamanaka, *Chem. Pharm. Bull.* **1987**, *35*, 823–828; b) T. X. Neenan, G. M. Whitesides, *J. Org. Chem.* **1988**, *53*, 2489–2496; c) A. Arcadi, O. A. Attanasi, B. Guidi, E. Rossi, S. Santeusano, *Chem. Lett.* **1999**, 59–60.
[15] T. Nussbaumer, R. Neidlein, *Heterocycles* **2000**, *52*, 349–364.
[16] a) T. R. Kelly, C. T. Jagoe, Z. Gu, *Tetrahedron Lett.* **1991**, *32*, 4263–4266; b) K. C. Nicolaou, Y. He, F. Roschangar, N. P. King, D. Vourloumis, T. Li, *Angew. Chem.* **1998**, *110*, 89–92; *Angew. Chem. Int. Ed.* **1998**, *37*, 84–87; c) K. C. Nicolaou, N. P. King, R. V. Finlay, Y. He, F. Roschangar, D. Vourloumis, H. Vahlberg, F. Sarabia, S. Ninkovic, D. Hepworth, *Bioorg. Med. Chem.* **1999**, *7*, 665–697.
[17] H. C. Brown, S. K. Gupta, *J. Am. Chem. Soc.* **1975**, *97*, 5249–5255.
[18] B. C. Bishop, I. F. Cottrell, D. Hands, *Synthesis* **1997**, 1315–1320.
[19] a) A. Suzuki, *J. Organomet. Chem.* **1999**, *576*, 147–168; b) N. Miyaura, A. Suzuki, *Chem. Rev.* **1995**, *95*, 2457–2483.
[20] a) J. I. Uenishi, J. M. Bean, R. W. Armstrong, Y. Kishi, *J. Am. Chem. Soc.* **1987**, *109*, 4756–4758; b) T. Watanabe, N. Miyaura, A. Suzuki, *Synlett* **1992**, 207–210.
[21] M. Lai, D. Li, E. Oh, H. Liu, *J. Am. Chem. Soc.* **1993**, *115*, 1619–1628.
[22] J. R. Gage, D. A. Evans, *Org. Synth.* **1990**, *68*, 77–91.
[23] For a recent review, see: C. J. Cowden, I. Paterson, *Org. React.* **1997**, *51*, 1–200.
[24] K. E. Drouet, E. A. Theodorakis, *J. Am. Chem. Soc.* **1999**, *121*, 456–457.
[25] a) H. Meerwein, F. Werner, H. Schön, G. Stopp, *Liebigs Ann.* **1961**, *641*, 1–23; b) D. A. Evans, A. M. Ratz, B. E. Huff, G. S. Sheppard, *J. Am. Chem. Soc.* **1995**, *117*, 3448–3467.
[26] D. B. Dess, J. C. Martin, *J. Org. Chem.* **1983**, *48*, 4156–4158.
[27] M. F. Lipton, A. Basha, S. M. Weinreb, *Org. Synth.* **1980**, *59*, 49–53.
[28] S. Nahm, S. M. Weinreb, *Tetrahedron Lett.* **1981**, *22*, 3815–3818.
[29] For alternative routes towards β -methoxyacrylates, see: a) B. J. Martin, J. M. Clough, G. Pattenden, I. R. Waldron, *Tetrahedron Lett.* **1993**, *34*, 5151–5154; b) D. Backhaus, *Tetrahedron Lett.* **2000**, *41*, 2087–2090.
[30] D. R. Coulson, *Inorg. Synth.* **1972**, *13*, 121–124.
[31] F. R. Hartley, *Organomet. Chem. Rev. Sect. A* **1970**, *6*, 119–137.
[32] T. Ukai, H. Kawazura, Y. Ishii, *J. Organomet. Chem.* **1974**, *65*, 253–266.
[33] M. Piber, Diplomarbeit, Universität Marburg, (Germany), **1999**.
[34] W. C. Still, M. Kahn, A. J. Mitra, *J. Org. Chem.* **1978**, *43*, 2923–2925.

Received: June 12, 2002 [F4174]